Elizabeth Radcliffe joined Cardurion in January, 2023. She brings over 20 years of industry experience, including progressive financial leadership roles across the full range of biopharmaceutical R&D, commercial and business operations at large and small organizations, both public and private. Prior to Cardurion, she served as Chief Financial Officer of Affinivax, where she led the buildout of the finance and IT functions and oversaw the sale of the company to GSK for up to $3.3 billion. Earlier leadership roles included Vice President, Finance & Strategy and Treasurer of Arrakis Therapeutics, and Vice President, Financial Planning & Analysis of Agios Pharmaceuticals, during the company’s first commercial product launch. She previously spent over a decade at Biogen, including roles leading R&D Finance, US Revenue Planning & Brand Finance, Corporate FP&A and Portfolio Management. Early in her career, Ms. Radcliffe held consulting positions at The Parthenon Group and Excelon Corporation.
Ms. Radcliffe received a B.S. in Chemistry from Yale University, an A.M. in Organic Chemistry from Harvard University, and an MBA from the M.I.T. Sloan School of Management.